Why IDS/IPS Agents Fail on Medical Devices

Part of our Hospital network, IoMT, and connected medical device security series. For the full overview, start with IEC 80001-1: Hospital Network Risk Management Explained.

When most industries think about intrusion detection (IDS) or intrusion prevention (IPS), they imagine installing agents directly on endpoints. But in the world of medical devices, that approach rarely works - and can even create risks for patient safety. Devices like infusion pumps, ventilators, imaging systems, and surgical robots don’t operate like corporate laptops or servers. They have strict performance constraints, regulatory requirements, and clinical safety considerations that make traditional endpoint security impractical.

In this blog, we’ll explain why agents don’t fit medical devices, the strategies that work, and how these align with FDA expectations for medical device cybersecurity.

Why this matters

The security of medical devices significantly impacts patient care delivery and patient safety outcomes. Deploying unsuitable agent-based security solutions can introduce critical vulnerabilities, degrade device performance, or even cause device failures, directly jeopardizing patient well-being. Such actions can invalidate manufacturer warranties and compliance certifications, leading to costly regulatory penalties and operational disruptions for healthcare delivery organizations. The FDA's 'Cybersecurity in Medical Devices' Final Guidance dated February 3, 2026, emphasizes a risk-based approach to medical device cybersecurity, advocating for controls that do not interfere with device function or patient safety. The guidance aligns with international standards such as IEC 81001-5-1, ISO/IEC 27001, and AAMI TIR97, which call for appropriate, non-intrusive security measures tailored to the unique constraints of medical technology. Understanding these limitations and adopting alternative, agent-less security strategies is essential for maintaining device functionality, ensuring patient safety, and achieving regulatory compliance in the medical device ecosystem.

Why Agents Aren’t Feasible on Medical Devices

Medical devices often run on constrained embedded operating systems (RTOS, embedded Linux) or legacy Windows builds. These systems are designed for reliability and performance, not for handling resource-heavy agents. Here’s why agents aren’t viable:

• Resource constraints: CPU, memory, and storage are limited; an agent could cause performance degradation.
• Regulatory and vendor support: Adding an agent may void FDA clearance or vendor warranties.
• Patient safety risks: An agent crash or false positive could disrupt care delivery in real time.
• Legacy designs: Many devices weren’t built with the ability to support third-party applications.

For these reasons, installing IDS/IPS or EDR-style agents directly on medical devices is generally not an option.

Practical Alternatives for Medical Devices

Since on-device agents aren’t feasible, healthcare organizations and manufacturers rely on network- and system-level protections that work around device limitations.

1. Network-Based IDS/IPS

• Passive IDS sensors monitor traffic from devices without touching the device itself.
• Inline IPS gateways enforce rules at the network edge, blocking malicious activity like command injection or ransomware traffic.
• Works well for protecting infusion pumps, imaging modalities, and monitoring systems without altering their configuration.

2. Micro-Segmentation and Allowlists

• Devices are grouped into role-based VLANs (e.g., imaging, monitoring, therapy).
• Least-privilege ACLs ensure devices only talk to PACS, EMR, or update servers.
• Prevents lateral movement and blocks Internet exposure by default.

3. Clinical Security Gateways and Proxies

• Gateways sit between devices and hospital networks, providing:
• Protocol validation (e.g., DICOM, HL7).
• Malware filtering and virtual patching.
• TLS termination and inspection when appropriate.

4. Using Device-Native Capabilities

• Secure logging: Forward syslog or export logs to SIEM if supported.
• Signed updates and secure boot: Ensure authenticity of firmware and updates.
• Audit trails: Use built-in logging to monitor clinical use and detect anomalies.

5. Passive Asset Discovery + SBOM Use

• Passive tools discover devices without active scanning.
• SBOMs (Software Bill of Materials) map known vulnerabilities to deployed assets.
• Risk-prioritized controls (segmentation, IPS rules) are applied when patching isn’t possible.

6. Network Access Control (NAC)

• Enforces that only approved medical devices connect to clinical VLANs.
• Rogue or noncompliant devices are quarantined automatically.

7. Change Control and Safety Testing

• Every segmentation or IPS rule change is validated in a clinical safety lab.
• Ensures new rules don’t disrupt patient care or critical device functionality.

When a Lightweight Agent Might Work

In rare cases, newer Windows-based devices may support vendor-approved lightweight monitoring agents. Even then, these should be used for visibility only (e.g., log forwarding, asset inventory), not prevention or enforcement. Safety and vendor approval must always come first.

Decision Guide for IDS/IPS in Medical Devices

Is the device vendor-supported for agents?

See also: What Is MedTech? MedTech vs Medical Device vs Life Sciences, CVSS Scoring for Medical Devices: A Complete Walkthrough, and Medical Device Software Development: A Compliance Guide.

• No → Use network-based IDS/IPS + segmentation.
• Yes (documented) → Consider visibility-only agents, with network IPS for enforcement.

Can the device tolerate inline inspection?

• Yes → Place inline IPS at gateways; latency-test and allowlist.
• No/Unknown → Rely on passive IDS + ACLs/micro-segmentation.

Is patching unavailable?

• Apply virtual patching at IPS, restrict egress, monitor via passive IDS.

Alignment with FDA Guidance

The FDA emphasizes that cybersecurity is part of medical device safety throughout the Total Product Lifecycle (TPLC). While FDA does not require agents on devices, it does expect:

• Risk-based controls (threat modeling, secure updates, validated logging).
• Compensating controls when patching isn’t feasible (e.g., segmentation, IDS/IPS).
• Postmarket monitoring via secure logs and network visibility.

Healthcare providers and manufacturers can meet regulatory expectations while protecting patients by adopting layered network protections and using existing device features.

Final Thoughts

Traditional endpoint security agents don’t fit the medical device environment. Instead, manufacturers and healthcare providers must rely on network-based defenses, segmentation, and secure processes to detect and prevent intrusions without compromising patient safety.

At Blue Goat Cyber, we help manufacturers and healthcare systems design practical, FDA-aligned cybersecurity strategies that integrate IDS and IPS effectively - without introducing unnecessary risk. The goal is always the same: protect patients, maintain trust, and ensure safe, reliable care.

Agent based and network based monitoring compared

The argument against agents on medical devices is not ideological. It is that an agent changes the validated configuration of a regulated product.

The compromise most hospitals land on is network monitoring for the device fleet and agents only on the general purpose computers that support it.

How Blue Goat approaches this

The Blue Goat Cyber approach acknowledges that medical devices require security tailored to their unique operational and regulatory landscapes. We specialize in identifying security vulnerabilities without disrupting clinical workflows or device functionality. Our methodology includes thorough threat modeling, penetration testing (by OSCP and ex-military red team experts), and thorough risk assessments that consider the entire medical device ecosystem. We focus on network-level controls, secure configurations, and clinical security gateway strategies that protect devices without requiring burdensome on-device agents. For manufacturers, our team, including CISSP-certified professionals, assists with pre-market and post-market cybersecurity submissions, ensuring alignment with the FDA's rigorous expectations. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

Learn more about our services: FDA Premarket Cybersecurity Services

FAQ

Why can't I install IDS/IPS agents on medical devices?

Medical devices have strict performance and reliability requirements. Traditional agents can consume too many resources (CPU, memory), disrupt device function, or invalidate the device's FDA clearance or vendor warranty, posing risks to patient safety.

What are the alternatives to agents for medical device security?

Effective alternatives include network-based intrusion detection/prevention systems, micro-segmentation, clinical security gateways, passive asset discovery, and using native device security features like secure boot and audit trails.

How does this align with the FDA's cybersecurity guidance?

The FDA's February 3, 2026 final guidance on premarket cybersecurity emphasizes risk-based controls and compensating controls for unpatchable vulnerabilities, such as network segmentation and IDS/IPS. It supports layered defenses that do not compromise device safety.

Does the FDA mandate specific cybersecurity technologies for medical devices?

No, the FDA does not mandate specific technologies. Instead, it expects manufacturers to implement risk-based cybersecurity controls throughout the Total Product Lifecycle (TPLC) to ensure device safety and effectiveness. This often requires adopting a combination of controls tailored to device specifics.

Can lightweight agents ever be used on medical devices?

In rare instances, newer Windows-based medical devices might support vendor-approved lightweight agents for visibility (e.g., logging, asset inventory). However, these should not be for prevention or enforcement, and patient safety and vendor approval remain paramount.

What risks do agents pose to patient safety if installed on medical devices?

An agent could cause performance degradation, system crashes, or false positives that disrupt device operation, potentially delaying or interfering with critical care delivery. This direct impact on device functionality creates unacceptable patient safety risks.

Related: The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks

More on this topic

• QIH Medical Devices Explained
• Why Is “Insecure” Used Instead
• CVSS 3.1 vs 4.0 for Medical Devices
• Write Blocker: Forensic Use, Types